| Primary information |
|---|
| sequence ID | Seq_6666 |
| Peptide sequence | RNVSTGDVNVE |
| CancerPDF_ID | CancerPDF_ID9211, CancerPDF_ID9822, CancerPDF_ID12074, |
| PMID | 24694173,21533267,26992070 |
| Protein Name | "Keratin, type I cytoskeletal 10","Keratin, type I cytoskeletal 10","Keratin, type I cytoskeletal 10" |
| UniprotKB Entry Name | K1C10_HUMAN,K1C10_HUMAN,K1C10_HUMAN |
| Fluid | Ascites fluid,Serum,Serum |
| M/Z | NA,595.3,1188.5735 |
| Charge | 1,2,NA |
| Mass (in Da) | NA,NA,NA |
| fdr | NA,NA,NA |
| Profiling Technique | LTQ-Orbitrap XL,LC-MS,LC-MS |
| Peptide Identification technique | X tandem for peptide identification,LC/MS/MS,LC-MS/MS |
| Quantification Technique | NA,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free |
| FDR | NA,1.49,FDR 1 % |
| CancerPDF_ID | CancerPDF_ID9211, CancerPDF_ID9822, CancerPDF_ID12074, |
| p-Value | NA,NA,NA |
| Software | "X tandem for peptide identification,Scaffold 2 software for any modification analysis",MASCOT,SEQUEST and Maxquant |
| Length | 11,11,11 |
| Cancer Type | Ovarian cancer,Lung adenocarcinoma,Melanoma |
| Database | IPI00009865,Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,NA |
| Number of Patients | 3 ovarian cancer patient and 3 non cancerous control,62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples |
| Regulation | Uniquely expressed in ovarian cancer patient,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Present in 5 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." |
| Validation | NA,MRM-based validation of 19 candidates,na |
| Sensitivity | NA,NA,NA |
| Specificity | NA,NA,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | 440063
|